ω-Conotoxin GVIA |
| Catalog No.GC13886 |
ω-Conotoxin GVIA는 해산물의 독소로 뉴런의 N형 채널을 선택적으로 차단한다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 106375-28-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
ω-Conotoxin GVIA는 해산물의 독소로 뉴런의 N형 채널을 선택적으로 차단한다.ω-Conotoxin GVIA는 인간 신변엽, 쥐 해마구리, 닭 뇌의 섬유질막에 결합 한다(IC50s = 46, 60, 150 pM, 각각 radioligand에서 구속력 있는 검사)[3,4,5]. ω-Conotoxin GVIA는 쥐의 정박경 앞 쪽 근의 연속 수축 강도를 현저하게 감소시켰지만, 연속 수축 촉진은 손상되지 않았다. 직접 전기 자극으로 유발된 근 수축은 ω-Conotoxin GVIA에 의해 현저하게 변경되지 않았다. ω-Conotoxin GVIA는 전신적 혈압에서 유의미한 변화가 없었다[5].
References:[1]. H.D. Mansvelder, J.C. Stoof, K.S. Kits. Dihydropyridine block of ω-agatoxin IVA- and ω-conotoxin GVIA-sensitive Ca2+ channels in rat pituitary melanotropic cells.Eur. J. Pharmacol., 311 (1996), pp. 293-304[2]. Feuerstein, T.J., Dooley, D.J., and Seeger, W. Inhibition of norepinephrine and acetylcholine release from human neocortex by ω-conotoxin GVIA. J. Pharmacol. Exp. Ther. 252(2), 778-785 (1990).[3]. Lampe, R.A., Lo, M.M., Keith, R.A., et al. Effects of site-specific acetylation on ω-conotoxin GVIA binding and function. Biochemistry 32(13), 3255-3260 (1993).[4]. Sato, K., Park, N.G., Kohno, T., et al. Role of basic residues for the binding of ω-conotoxin GVIA to N-type calcium channels. Biochem. Biophys. Res. Commun. 194(3), 1292-1296 (1993).[5]: Rossoni G, Berti F, La Maestra L, Clementi F. ω-Conotoxin GVIA binds to and blocks rat neuromuscular junction. Neuroscience Letters. 1994;176:185-188.| 세포 실험 [1]: | |
세포 라인 | 쥐 뇌하수체 멜라놉트롭 세포 |
제조 방법 | ω-Conotoxin GVIA는 중력 구동 Y형 시스템이나 프레셔 제트를 통해 투여되었습니다. 기록용 실험실은 공기압에 의해 1.5ml/분의 속도로 지속적으로 혼입되고 지속적인 흡입을 통해 욕조용량을 일정하게 유지했습니다. 전기 생리학 테스트가 실시되었습니다. |
반응 조건 | 1 or 10 µM |
응용 분야 | 1 µM ω-Conotoxin GVIA는 고전압 활성화된 전류를 25.5±3.6% 차단하였습니다. 10µM ω-Conotoxin GVIA의 차단률은 22.9±2.5%였으며 (1 µM의 차단과 유의미한 차이가 없습니다; n = 3), ω-Conotoxin GVIA가 포화효과를 일으킨다는 것을 나타냅니다. |
| 동물 실험 [2]: | |
동물 모형 | 수컷 COBS CD (SD) 쥐 |
제조 방법 | 이 동물에서 ω-Conotoxin GVIA의 등급된 용량을 정맥 주사 (1-2 nmol/kg) |
제형 | 정맥 주사, 1--2 nmol/kg |
응용 분야 | 정맥 주사로 인한 섭동근의 점진적인 긴장력 손실은 엉덩이 신경의 전기 자극에 의해 간접적으로 유발되었습니다. ω-Conotoxin GVIA (1nmol/kg i.v.)는 약 27분 내에 근육 수축의 강도를 75% 감소시켰습니다. |
참고문헌: [1]: H.D. Mansvelder, J.C. Stoof, K.S. Kits. Dihydropyridine block of ω-agatoxin IVA- and ω-conotoxin GVIA-sensitive Ca2+ channels in rat pituitary melanotropic cells.Eur. J. Pharmacol., 311 (1996), pp. 293-304 | |
| Cas No. | 106375-28-4 | SDF | |
| Canonical SMILES | C[C@](O)([H])[C@@](/N=C(O)/[C@](/N=C(O)/[C@]1([H])C[C@](O)([H])CN12)([H])CC3=CC=C(O)C=C3)([H])/C(O)=N/[C@@](/C(O)=N/[C@@](/C(O)=N\[C@@](/C(O)=N\[C@@](C(O)=N)([H])CC4=CC=C(O)C=C4)([H])CSSC[C@@](N=C(O)[C@](N=C(O)[C@](N=C(O)[C@](N=C(O)[C@](N=C(O)[C@]5([H])C[ | ||
| Formula | C120H182N38O43S6 | M.Wt | 3037.35 |
| Solubility | Soluble to 1 mg/ml in Water | Storage | Desiccate at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 0.3292 mL | 1.6462 mL | 3.2923 mL |
| 5 mM | 0.0658 mL | 0.3292 mL | 0.6585 mL |
| 10 mM | 0.0329 mL | 0.1646 mL | 0.3292 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 28 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *